Class information for:
Level 1: DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
18530 482 22.3 37%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1294 8163 FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DRUG LAG Author keyword 13 67% 2% 12
2 OFF PHARMACEUT IND Address 9 83% 1% 5
3 JAPANESE CLINICAL TRIALS Author keyword 6 100% 1% 4
4 STUDY DRUG DEV Address 4 31% 2% 11
5 PHARMACEUT REGULATORY SCI Address 4 38% 2% 8
6 APPROVAL TIMES Author keyword 3 100% 1% 3
7 CLIN TRIAL GUIDANCE Address 3 100% 1% 3
8 LABEL CHANGES Author keyword 3 100% 1% 3
9 PRESCRIPTION DRUG USER FEE ACT OF 1992 Author keyword 3 100% 1% 3
10 REVIEW AUDIT Address 3 100% 1% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 DRUG LAG 13 67% 2% 12 Search DRUG+LAG Search DRUG+LAG
2 JAPANESE CLINICAL TRIALS 6 100% 1% 4 Search JAPANESE+CLINICAL+TRIALS Search JAPANESE+CLINICAL+TRIALS
3 APPROVAL TIMES 3 100% 1% 3 Search APPROVAL+TIMES Search APPROVAL+TIMES
4 LABEL CHANGES 3 100% 1% 3 Search LABEL+CHANGES Search LABEL+CHANGES
5 PRESCRIPTION DRUG USER FEE ACT OF 1992 3 100% 1% 3 Search PRESCRIPTION+DRUG+USER+FEE+ACT+OF+1992 Search PRESCRIPTION+DRUG+USER+FEE+ACT+OF+1992
6 PRIORITY REVIEW 3 50% 1% 4 Search PRIORITY+REVIEW Search PRIORITY+REVIEW
7 CENTRALISED PROCEDURE 2 67% 0% 2 Search CENTRALISED+PROCEDURE Search CENTRALISED+PROCEDURE
8 FOOD AND DRUG ADMINISTRATION APPROVAL 2 67% 0% 2 Search FOOD+AND+DRUG+ADMINISTRATION+APPROVAL Search FOOD+AND+DRUG+ADMINISTRATION+APPROVAL
9 ICH E5 GUIDELINE 2 67% 0% 2 Search ICH+E5+GUIDELINE Search ICH+E5+GUIDELINE
10 REGISTRATION TRIAL 2 67% 0% 2 Search REGISTRATION+TRIAL Search REGISTRATION+TRIAL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 DRUG LAG 6 80% 1% 4
2 APPROVALS 6 50% 2% 8
3 DEVICES EVALUATION CENTER 6 100% 1% 4
4 ADMINISTRATION MODERNIZATION ACT 4 75% 1% 3
5 USER FEE ACT 4 75% 1% 3
6 ICH E5 GUIDELINE 3 100% 1% 3
7 PMDEC 3 100% 1% 3
8 MULTI REGIONAL TRIALS 2 67% 0% 2
9 UNDERSTANDING COMPARISONS 2 67% 0% 2
10 DISCONTINUATIONS 1 38% 1% 3

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Trends in development and approval times for new therapeutics in the United States 2003 98 9 100%
Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice 2011 21 2 100%
Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates 2005 36 7 71%
Racial/Ethnic Differences in Drug Disposition and Response: Review of Recently Approved Drugs 2015 3 32 25%
Drug-review deadlines and safety problems 2008 57 5 40%
European Union Centralised Procedure for marketing authorisation of oncology drugs: An in-depth review of its efficiency 2006 7 2 100%
Approval probabilities and regulatory review patterns for anticancer drugs in the European Union 2013 4 22 32%
FDA Review Divisions: Performance Levels and the Impact on Drug Sponsors 2012 3 3 67%
Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology 2002 11 2 100%
Critical review of 'Public domain application': a flexible drug approval system in Japan 2013 3 3 33%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OFF PHARMACEUT IND 9 83% 1.0% 5
2 STUDY DRUG DEV 4 31% 2.3% 11
3 PHARMACEUT REGULATORY SCI 4 38% 1.7% 8
4 CLIN TRIAL GUIDANCE 3 100% 0.6% 3
5 REVIEW AUDIT 3 100% 0.6% 3
6 TUFTS STUDY DRUG DEV 2 17% 1.9% 9
7 PHARMACEUT MED DEVICES EVALUAT 1 21% 1.2% 6
8 SOCIOL SUBJECT GRP 1 33% 0.4% 2
9 YOUNG LEADERS PROGRAM HLTH CARE ADM 1 33% 0.4% 2
10 CONSUMER LIAISON GRP 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000197424 ORPHAN DRUGS//RARE DISEASES//OFF ORPHAN PROD DEV
2 0.0000180479 MULTIPLE INDUSTRIES//RETURN ON INNOVATION//VALUE TRANSFERENCE
3 0.0000159126 PHARMACEUTICALISATION//CRHAM//CORPORATE BIAS
4 0.0000158644 FOOD AND DRUG LAW JOURNAL//HUMANITARIAN DEVICE EXEMPTION//PREMARKET APPROVAL
5 0.0000130990 GENERIC SUBSTITUTION//GENERIC DRUGS//REFERENCE PRICING
6 0.0000111825 CLINICAL TRIAL RISK//CONTINUOUS IMPROVEMENT//STRATEGIE IND
7 0.0000085392 HEALTH INSURANCE CLAIMS//MED HOSP MED CARE ADM//HEALTH INSURANCE CLAIM
8 0.0000066612 DRUG SHORTAGES//VACCINE STOCKPILES//VACCINE SHORTAGE
9 0.0000062921 BRIDGING STUDY//MULTIREGIONAL CLINICAL TRIAL//MULTIREGIONAL TRIAL
10 0.0000061353 ACTIVATION SYNDROME//RISK EVALUATION AND MITIGATION STRATEGIES//REGULATORY ACTIONS